Cargando…

S108: A SYSTEMATIC POST-MARKETING (PM) REVIEW OF RARE INFUSION-RELATED REACTIONS (IRRS) PRESENTING AS PAIN EVENTS DURING OR AFTER CRIZANLIZUMAB INFUSION IN PATIENTS WITH SICKLE CELL DISEASE (SCD)

Detalles Bibliográficos
Autores principales:	Kanter, J, Shah, A, Joshi, V, Mehta, H, Levine, M, Arunagiri, U, Paulose, J, Donohue, B, Scalera, A, Manwani, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Oral Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811864/ http://dx.doi.org/10.1097/01.HS9.0000821400.77896.85

Ejemplares similares

5613436 EXPERT CONSENSUS ON THE MANAGEMENT OF INFUSION-RELATED REACTIONS (IRRS) PRESENTING WITH PAIN IN PATIENTS RECEIVING CRIZANLIZUMAB
por: Kanter, J., et al.
Publicado: (2023)

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease
por: Kanter, Julie, et al.
Publicado: (2022)

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS
por: Abboud, Miguel, et al.
Publicado: (2023)

S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL
por: Heeney, M, et al.
Publicado: (2022)

Successful Treatment of SCD-Related Priapism With Crizanlizumab: A Case Series
por: Idowu, Modupe, et al.
Publicado: (2023)

S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)
por: Anderson, Alan, et al.
Publicado: (2023)

Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report
por: Alshurafa, Awni, et al.
Publicado: (2022)

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
por: Buka, Richard J, et al.
Publicado: (2022)

Real-World Data of Crizanlizumab in Sickle Cell Disease: A Single-Center Analysis
por: Cheplowitz, Halle, et al.
Publicado: (2023)

Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date
por: Riley, Tanya R, et al.
Publicado: (2019)

Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis
por: Thom, Howard, et al.
Publicado: (2020)

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
por: Migotsky, Michael, et al.
Publicado: (2022)

48847 Assessing Transition Outcomes in Sickle Cell Disease (SCD) Prior To Implementation of A Formal Transition Program
por: Sheppard, Sydney, et al.
Publicado: (2021)

Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease
por: Osunkwo, Ifeyinwa, et al.
Publicado: (2020)

S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP)
por: Silva-Pinto, A, et al.
Publicado: (2022)

P-030: CRIZANLIZUMAB REDUCES ENDOTHELIAL ADHESION OF RED BLOOD CELLS FROM SCD PATIENTS IN STANDARDIZED MICROFLUIDIC PLATFORM: IN VITRO TECHNOLOGY ASSESSMENT
por: C., FEDERICI, et al.
Publicado: (2022)

P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
por: Silva-Pinto, A. C., et al.
Publicado: (2022)

GRNDaD: big data and sickle cell disease
por: Lanzkron, Sophie, et al.
Publicado: (2022)

P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab
por: Karki, Nabin Raj, et al.
Publicado: (2021)

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
por: Delgado, Julio, et al.
Publicado: (2021)

Role of the Irr Protein in the Regulation of Iron Metabolism in Rhodobacter sphaeroides
por: Peuser, Verena, et al.
Publicado: (2012)

Probing Structure and Function of Alkali Sensor IRR with Monoclonal Antibodies
por: Goryashchenko, Alexander S., et al.
Publicado: (2020)

O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
por: A., SILVA-PINTO, et al.
Publicado: (2022)

P1441: REAL-WORLD OUTCOMES AND DIGITALLY MONITORED QUALITY OF LIFE IN CRIZANLIZUMAB-TREATED PATIENTS WITH SICKLE CELL DISEASE.
por: Summers, Kim, et al.
Publicado: (2023)

S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY
por: Heeney1, Matthew, et al.
Publicado: (2023)

More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
por: Langley, Paul C
Publicado: (2020)

Engineering prokaryotic regulator IrrE to enhance stress tolerance in budding yeast
por: Wang, Li, et al.
Publicado: (2020)

Crizanlizumab: A CRITICAL Drug During a CRITICAL Time?
por: Gue, Ying X., et al.
Publicado: (2021)

Biomarkers for nonclinical infusion reactions in marketed biotherapeutics and considerations for study design
por: Mease, Kirsten M., et al.
Publicado: (2017)

PI-01: GRNDAD AND COUSIN: INVESTIGATOR-INITIATED COLLABORATIONS TO IMPROVE CARE IN SICKLE CELL DISEASE
por: J., LITTLE, et al.
Publicado: (2022)

Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review
por: Dick, Maurice H, et al.
Publicado: (2022)

High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study
por: Kanter, Julie, et al.
Publicado: (2019)

The Neonatal Screening Program in Brazil, Focus on Sickle Cell Disease (SCD)
por: Silva-Pinto, Ana C., et al.
Publicado: (2019)

Transition in Sickle Cell Disease (SCD): A German Consensus Recommendation
por: Alashkar, Ferras, et al.
Publicado: (2022)

Types and Frequency of Infusion Pump Alarms and Infusion-Interruption to Infusion-Recovery Times for Critical Short Half-Life Infusions: Retrospective Data Analysis
por: Waterson, James, et al.
Publicado: (2019)

Saline Infusion
Publicado: (1908)

The Indications for Infusion
Publicado: (1910)

Pharmaceutical Quality of Selected Metronidazole and Ciprofloxacin Infusions Marketed in South Eastern Nigeria
por: Oli, Angus Nnamdi, et al.
Publicado: (2020)

Escort cell encapsulation of Drosophila germline cells is maintained by irre cell recognition module proteins
por: Ben-Zvi, Doreen S., et al.
Publicado: (2019)

Development of an open-source soil water potential management system for horticultural applications, “Open_Irr”
por: Bierer, Andrew M.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mg0u4lnbthn9gna7dmelts5r58